New hope for advanced prostate cancer: experimental drug cocktails enter human testing
NCT ID NCT07198633
First seen Nov 01, 2025
Summary
This study tests several new drug combinations for men with advanced prostate cancer that has spread. The experimental drugs include QLC5508 (a targeted therapy that delivers a toxin to cancer cells) and QLH12016 (a drug that breaks down the male hormone receptor). These are combined with standard hormone therapies. The trial has two phases: first, finding the safest dose, and then checking if the combinations shrink tumors or lower PSA levels. About 212 men will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLC5508 (a targeted antibody-drug conjugate) and QLH12016 (an oral drug that degrades the androgen receptor), combined with standard hormone therapies abiraterone or enzalutamide
What this could lead to
If successful, this could point toward more effective combination treatments for advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so the main goals are safety and dosing—not yet proof of effectiveness. Side effects from the new drug combinations are unknown, and many early-stage cancer trials do not lead to approved treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.